A Weight Loss Drug Candidate Essentially For Free As Skye Bioscience Is Trading At Cash Value [Seeking Alpha]
Skye Bioscience, Inc. (SKYE)
Company Research
Source: Seeking Alpha
This presents potential value opportunities in a market projected to grow to $105 billion by 2035. Skye Bioscience's nimacimab, in Phase 2a trials, shows promise with significant weight loss results in mouse models, making it a speculative but potentially rewarding investment. 26-week results for the Phase 2a are expected in late Q3 or early Q4, so positive catalysts are on the horizon. SKYE currently trades essentially at cash value, meaning investors who buy in today get a weight loss drug candidate essentially for free. Jose Luis Pelaez Inc Weight loss drug companies have come off of their peak hype from about a year ago. Novo Nordisk A/S ( NVO ), manufacturer of Ozempic and Wegovy, has seen its stock price cut by more than half Recommended For You
Show less
Read more
Impact Snapshot
Event Time:
SKYE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SKYE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SKYE alerts
High impacting Skye Bioscience, Inc. news events
Weekly update
A roundup of the hottest topics
SKYE
News
- Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of January 16, 2026 in Skye Bioscience, Inc. Lawsuit - SKYEPR Newswire
- Bragar Eagel & Squire, P.C. Urges DeFi, Skye Bioscience, and Perrigo Investors to Contact the Firm Regarding their RightsGlobeNewswire
- Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Skye Bioscience, Inc. (SKYE) ShareholdersGlobeNewswire
- SKYE Investors Have Opportunity to Lead Skye Bioscience, Inc. Securities Fraud LawsuitPR Newswire
- ROSEN, A LONGSTANDING LAW FIRM, Encourages Skye Bioscience, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SKYEGlobeNewswire
SKYE
Earnings
- 11/10/25 - Beat
SKYE
Sec Filings
- 11/10/25 - Form 8-K
- 11/10/25 - Form 10-Q
- SKYE's page on the SEC website